Trials / Completed
CompletedNCT01924143
TD-9855 Mass Balance Study
An Open-Label Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of TD-9855 Following a Single Oral Dose Containing Approximately 100 µCi [14C]-Labeled TD-9855 (20 mg) in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Theravance Biopharma · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to evaluate the absorption, distribution, metabolism, and excretion (ADME) of a single oral dose of \[14C\]TD-9855
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TD-9855 | radiolabeled (100 µCi \[14C\]-Labeled) TD-9855 (20 mg) |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2013-11-01
- Completion
- 2013-12-01
- First posted
- 2013-08-16
- Last updated
- 2021-01-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01924143. Inclusion in this directory is not an endorsement.